First-line antiretroviral therapy with a protease inhibitor versus non-nucleoside reverse transcriptase inhibitor and switch at higher versus low viral load in HIV-infected children: an open-label, randomised phase 2/3 trial

The PENPACT-1 (PENTA 9/PACTG 390) Study Team . Lancet Infect Dis . 2011 Apr 11; 11 (4) :273-283.

Get This Resource

English: Web site

Summary

Abstract. The full article is available with registration.

Publisher:	Elsevier
Language:	English
Format:	Web site
Region:	Global
Audiences:	Doctors/Physicians, Researchers, Physician's Assistants/Nurse Practitioners
Topic Area:	Pediatric Antiretroviral Treatment
Resource Type:	Journal Articles

Contact | Feedback | Subscribe | Disclaimer | Site Map

Women, Children, and HIV is a project of the UCSF Center for HIV Information (CHI). Copyright 2013, Regents of the University of California. E-mail Editor@WomenChildrenHIV.org with questions or comments.

First-line antiretroviral therapy with a protease inhibitor versus non-nucleoside reverse transcriptase inhibitor and switch at higher versus low viral load in HIV-infected children: an open-label, randomised phase 2/3 trial

Get This Resource

Summary

Featured Resources